A detailed history of Rhumbline Advisers transactions in Enanta Pharmaceuticals Inc stock. As of the latest transaction made, Rhumbline Advisers holds 34,566 shares of ENTA stock, worth $392,324. This represents 0.0% of its overall portfolio holdings.

Number of Shares
34,566
Previous 33,018 4.69%
Holding current value
$392,324
Previous $576,000 22.22%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 01, 2024

BUY
$11.43 - $17.02 $17,693 - $26,346
1,548 Added 4.69%
34,566 $448,000
Q1 2024

May 09, 2024

BUY
$10.08 - $17.46 $7,096 - $12,291
704 Added 2.18%
33,018 $576,000
Q4 2023

Feb 08, 2024

SELL
$8.18 - $10.78 $1,357 - $1,789
-166 Reduced 0.51%
32,314 $304,000
Q3 2023

Nov 09, 2023

SELL
$11.09 - $22.13 $357,807 - $714,002
-32,264 Reduced 49.83%
32,480 $362,000
Q2 2023

Aug 08, 2023

BUY
$20.68 - $39.85 $18,239 - $35,147
882 Added 1.38%
64,744 $1.39 Million
Q1 2023

May 11, 2023

BUY
$38.82 - $54.59 $147,477 - $207,387
3,799 Added 6.33%
63,862 $2.58 Million
Q4 2022

Feb 14, 2023

BUY
$40.77 - $53.73 $2,446 - $3,223
60 Added 0.1%
60,063 $2.79 Million
Q3 2022

Nov 10, 2022

BUY
$48.29 - $71.27 $203,928 - $300,973
4,223 Added 7.57%
60,003 $3.11 Million
Q2 2022

Aug 11, 2022

BUY
$38.13 - $76.93 $78,357 - $158,091
2,055 Added 3.83%
55,780 $2.64 Million
Q1 2022

May 12, 2022

SELL
$56.06 - $74.11 $23,040 - $30,459
-411 Reduced 0.76%
53,725 $3.82 Million
Q4 2021

Feb 10, 2022

SELL
$60.19 - $97.37 $61,634 - $99,706
-1,024 Reduced 1.86%
54,136 $4.05 Million
Q3 2021

Nov 12, 2021

SELL
$41.02 - $58.65 $278,771 - $398,585
-6,796 Reduced 10.97%
55,160 $3.13 Million
Q2 2021

Aug 05, 2021

SELL
$43.76 - $53.11 $177,796 - $215,785
-4,063 Reduced 6.15%
61,956 $2.73 Million
Q1 2021

May 06, 2021

BUY
$41.69 - $54.95 $31,767 - $41,871
762 Added 1.17%
66,019 $3.26 Million
Q4 2020

Feb 10, 2021

BUY
$41.16 - $47.47 $234,529 - $270,484
5,698 Added 9.57%
65,257 $2.75 Million
Q3 2020

Nov 12, 2020

SELL
$43.36 - $53.53 $90,362 - $111,556
-2,084 Reduced 3.38%
59,559 $2.73 Million
Q2 2020

Aug 13, 2020

BUY
$46.37 - $57.58 $172,218 - $213,852
3,714 Added 6.41%
61,643 $3.1 Million
Q1 2020

May 06, 2020

BUY
$40.22 - $62.0 $153,640 - $236,840
3,820 Added 7.06%
57,929 $2.98 Million
Q4 2019

Feb 05, 2020

BUY
$57.95 - $66.61 $186,599 - $214,484
3,220 Added 6.33%
54,109 $3.34 Million
Q3 2019

Oct 23, 2019

BUY
$60.08 - $88.17 $72,937 - $107,038
1,214 Added 2.44%
50,889 $3.06 Million
Q2 2019

Aug 14, 2019

BUY
$81.3 - $97.35 $225,770 - $270,340
2,777 Added 5.92%
49,675 $4.19 Million
Q1 2019

May 01, 2019

BUY
$69.08 - $105.66 $10,016 - $15,320
145 Added 0.31%
46,898 $4.48 Million
Q4 2018

Jan 31, 2019

BUY
$65.41 - $84.65 $570,506 - $738,317
8,722 Added 22.93%
46,753 $3.31 Million
Q3 2018

Nov 07, 2018

BUY
$85.46 - $126.37 $41,106 - $60,783
481 Added 1.28%
38,031 $3.25 Million
Q2 2018

Aug 06, 2018

BUY
$81.85 - $120.51 $56,558 - $83,272
691 Added 1.87%
37,550 $4.35 Million
Q1 2018

May 02, 2018

BUY
$57.91 - $92.15 $22,237 - $35,385
384 Added 1.05%
36,859 $2.98 Million
Q4 2017

Feb 09, 2018

BUY
$45.65 - $59.37 $204,329 - $265,740
4,476 Added 13.99%
36,475 $2.14 Million
Q3 2017

Nov 06, 2017

BUY
$37.91 - $46.8 $1.21 Million - $1.5 Million
31,999
31,999 $1.5 Million

Others Institutions Holding ENTA

About ENANTA PHARMACEUTICALS INC


  • Ticker ENTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,724,900
  • Market Cap $235M
  • Description
  • Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...
More about ENTA
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.